3SBio Inc.

Nov 23, 2020

3SBio Inc. received milestone payment of USD 4 million upon commencement of phase III clinical program of SEL-212

Mar 31, 2020

3SBio Unveils 2019 Annual Results: Revenue Rises by 16.0%, Normalized Net Profit attributable to owners of the parent Jumps by19.4%, R&D Expenses Soar 45.2%

Mar 01, 2020

3SBIO makes investment in MPM's $100M Oncology Innovations Fund and donation to Dana-Farber cancer research

Nov 17, 2019

3SBio Selects Verseau's PSGL-1-targeted Antibody VTX-0811 as First Partnered Macrophage Checkpoint Modulator in Immuno-Oncology Collaboration

Mar 03, 2019

3SBio and TLC Form Exclusive Partnership to Commercialize Two NanoX(TM) Products in Mainland China

Feb 11, 2019

3SBio and Verseau Establish Global Clinical Development Collaboration for First-in-class Immuno-Oncology Therapies

Jan 06, 2019

3SBio and Samsung Bioepis enter biosimilar collaboration agreement

Sep 03, 2017

Therapure Biopharma Inc. Announces Spin Off and Sale of Contract Development and Manufacturing Business for US$290 Million

Sep 03, 2017

3SBio Accelerates Expansion of its Global Biologics Platform by Acquiring the Canadian Biomanufacturing Business of Therapure